While the efficacy of inhibitors targeting the other Hsp90 protein, such as Ganetespib (STA-9090) and luminespib (AUY922), has been demonstrated in certain cancers, including hepatocellular carcinoma (HCC) (192), pancreatic cancer (PC) (193), gastric cancer (GC) (194, 195). This evidence concerns the gene HSP90AA1 and pachyonychia congenita.